Cargando…
The clinical role of the TME in solid cancer
The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts, and a variety of immune cells that control tumour growth and invasion. It is well established that anti-tumour immunit...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325164/ https://www.ncbi.nlm.nih.gov/pubmed/30413828 http://dx.doi.org/10.1038/s41416-018-0327-z |
_version_ | 1783386090018701312 |
---|---|
author | Giraldo, Nicolas A. Sanchez-Salas, Rafael Peske, J. David Vano, Yann Becht, Etienne Petitprez, Florent Validire, Pierre Ingels, Alexandre Cathelineau, Xavier Fridman, Wolf Herman Sautès-Fridman, Catherine |
author_facet | Giraldo, Nicolas A. Sanchez-Salas, Rafael Peske, J. David Vano, Yann Becht, Etienne Petitprez, Florent Validire, Pierre Ingels, Alexandre Cathelineau, Xavier Fridman, Wolf Herman Sautès-Fridman, Catherine |
author_sort | Giraldo, Nicolas A. |
collection | PubMed |
description | The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts, and a variety of immune cells that control tumour growth and invasion. It is well established that anti-tumour immunity is a critical hurdle that must be overcome for tumours to initiate, grow and spread and that anti-tumour immunity can be modulated using current immunotherapies to achieve meaningful anti-tumour clinical responses. Pioneering studies in melanoma, ovarian and colorectal cancer have demonstrated that certain features of the tumour immune microenvironment (TME)—in particular, the degree of tumour infiltration by cytotoxic T cells—can predict a patient’s clinical outcome. More recently, studies in renal cell cancer have highlighted the importance of assessing the phenotype of the infiltrating T cells to predict early relapse. Furthermore, intricate interactions with non-immune cellular players such as endothelial cells and fibroblasts modulate the clinical impact of immune cells in the TME. Here, we review the critical components of the TME in solid tumours and how they shape the immune cell contexture, and we summarise numerous studies evaluating its clinical significance from a prognostic and theranostic perspective. |
format | Online Article Text |
id | pubmed-6325164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-63251642019-11-09 The clinical role of the TME in solid cancer Giraldo, Nicolas A. Sanchez-Salas, Rafael Peske, J. David Vano, Yann Becht, Etienne Petitprez, Florent Validire, Pierre Ingels, Alexandre Cathelineau, Xavier Fridman, Wolf Herman Sautès-Fridman, Catherine Br J Cancer Review Article The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts, and a variety of immune cells that control tumour growth and invasion. It is well established that anti-tumour immunity is a critical hurdle that must be overcome for tumours to initiate, grow and spread and that anti-tumour immunity can be modulated using current immunotherapies to achieve meaningful anti-tumour clinical responses. Pioneering studies in melanoma, ovarian and colorectal cancer have demonstrated that certain features of the tumour immune microenvironment (TME)—in particular, the degree of tumour infiltration by cytotoxic T cells—can predict a patient’s clinical outcome. More recently, studies in renal cell cancer have highlighted the importance of assessing the phenotype of the infiltrating T cells to predict early relapse. Furthermore, intricate interactions with non-immune cellular players such as endothelial cells and fibroblasts modulate the clinical impact of immune cells in the TME. Here, we review the critical components of the TME in solid tumours and how they shape the immune cell contexture, and we summarise numerous studies evaluating its clinical significance from a prognostic and theranostic perspective. Nature Publishing Group UK 2018-11-09 2019-01-08 /pmc/articles/PMC6325164/ /pubmed/30413828 http://dx.doi.org/10.1038/s41416-018-0327-z Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Review Article Giraldo, Nicolas A. Sanchez-Salas, Rafael Peske, J. David Vano, Yann Becht, Etienne Petitprez, Florent Validire, Pierre Ingels, Alexandre Cathelineau, Xavier Fridman, Wolf Herman Sautès-Fridman, Catherine The clinical role of the TME in solid cancer |
title | The clinical role of the TME in solid cancer |
title_full | The clinical role of the TME in solid cancer |
title_fullStr | The clinical role of the TME in solid cancer |
title_full_unstemmed | The clinical role of the TME in solid cancer |
title_short | The clinical role of the TME in solid cancer |
title_sort | clinical role of the tme in solid cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325164/ https://www.ncbi.nlm.nih.gov/pubmed/30413828 http://dx.doi.org/10.1038/s41416-018-0327-z |
work_keys_str_mv | AT giraldonicolasa theclinicalroleofthetmeinsolidcancer AT sanchezsalasrafael theclinicalroleofthetmeinsolidcancer AT peskejdavid theclinicalroleofthetmeinsolidcancer AT vanoyann theclinicalroleofthetmeinsolidcancer AT bechtetienne theclinicalroleofthetmeinsolidcancer AT petitprezflorent theclinicalroleofthetmeinsolidcancer AT validirepierre theclinicalroleofthetmeinsolidcancer AT ingelsalexandre theclinicalroleofthetmeinsolidcancer AT cathelineauxavier theclinicalroleofthetmeinsolidcancer AT fridmanwolfherman theclinicalroleofthetmeinsolidcancer AT sautesfridmancatherine theclinicalroleofthetmeinsolidcancer AT giraldonicolasa clinicalroleofthetmeinsolidcancer AT sanchezsalasrafael clinicalroleofthetmeinsolidcancer AT peskejdavid clinicalroleofthetmeinsolidcancer AT vanoyann clinicalroleofthetmeinsolidcancer AT bechtetienne clinicalroleofthetmeinsolidcancer AT petitprezflorent clinicalroleofthetmeinsolidcancer AT validirepierre clinicalroleofthetmeinsolidcancer AT ingelsalexandre clinicalroleofthetmeinsolidcancer AT cathelineauxavier clinicalroleofthetmeinsolidcancer AT fridmanwolfherman clinicalroleofthetmeinsolidcancer AT sautesfridmancatherine clinicalroleofthetmeinsolidcancer |